1. Home
  2. APPS vs EOLS Comparison

APPS vs EOLS Comparison

Compare APPS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digital Turbine Inc.

APPS

Digital Turbine Inc.

HOLD

Current Price

$5.00

Market Cap

503.5M

Sector

Miscellaneous

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$6.69

Market Cap

444.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPS
EOLS
Founded
N/A
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
444.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
APPS
EOLS
Price
$5.00
$6.69
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$6.25
$20.50
AVG Volume (30 Days)
2.1M
843.1K
Earning Date
02-04-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$525,092,000.00
$285,823,000.00
Revenue This Year
$13.99
$14.24
Revenue Next Year
$11.83
$21.77
P/E Ratio
N/A
N/A
Revenue Growth
6.82
15.10
52 Week Low
$1.65
$5.71
52 Week High
$8.28
$17.12

Technical Indicators

Market Signals
Indicator
APPS
EOLS
Relative Strength Index (RSI) 45.79 43.99
Support Level $5.00 $6.57
Resistance Level $5.27 $6.93
Average True Range (ATR) 0.26 0.23
MACD 0.02 -0.05
Stochastic Oscillator 33.49 16.23

Price Performance

Historical Comparison
APPS
EOLS

About APPS Digital Turbine Inc.

Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: